The FDA Just Rejected This Cancer Therapy. Again.

A Resubmission That Didn't Move the Needle

After the first rejection in July 2025, Replimune didn't go quietly. The company met with the FDA, ran additional analyses on RP1's mechanism of action, compared outcomes to prior treatments, and even gathered early data from its ongoing Phase 3 trial, IGNYTE-3. Twenty-two investigators signed an open letter urging the FDA to reconsider. Replimune resubmitted its application in October 2025.

The FDA assembled a new review team, pulling in the Office of Therapeutic Products and the Oncology Center of Excellence for a fresh look. That team unanimously reached the same conclusion: the data weren't sufficient to prove RP1 actually works.

The early Phase 3 data? Dismissed. Only 10% of planned patients had been enrolled, there was no duration-of-response data, and the progression-free survival analysis hadn't been pre-specified (meaning it was essentially an afterthought, not part of the original study plan). The FDA characterized these results as too immature to matter.

For Replimune, this was the regulatory equivalent of turning in extra credit and still failing the exam.

Why This Matters Beyond One Company

RP1's rejection isn't just a Replimune problem. It's a signal flare for the entire oncolytic virus space.

Right now, only one oncolytic virus therapy is FDA-approved in the United States: Amgen's T-VEC (Imlygic), greenlit back in 2015 for melanoma. The field has been promising "next-generation" viral therapies for a decade, but the regulatory path remains brutally narrow. Dozens of companies are developing oncolytic virus therapies, and the market is projected to hit $0.29 billion in 2026. That sounds like growth until you realize most of that value still rests on a single approved product.

The FDA's message is clear: if you're going to combine your experimental therapy with an already-approved drug, you need a randomized controlled trial to prove your addition matters. Single-arm studies, no matter how promising the numbers look, won't cut it. This sets a high bar for dozens of companies chasing similar approvals with similar trial designs.

What's Left in the Tank?

Replimune isn't dead yet, but it's on life support. The company had previously warned in SEC filings that another rejection could effectively end RP1's development. Its confirmatory Phase 3 trial (IGNYTE-3), which randomizes patients to RP1 plus nivolumab versus standard care with an overall survival endpoint, is still ongoing. That leaves a long wait ahead.

The stock tells the story. Shares that once traded in double digits have been hovering in the low single digits, with recent prices ranging from roughly $1.75 to $8.80 depending on the timeframe. Analyst opinions are split: some still see 100%+ upside potential, while multiple firms downgraded the stock after the first rejection.

For Replimune, the math is unforgiving. Burning cash for years while waiting on Phase 3 data, with a stock price in the basement and two FDA rejections on the books, is the biotech equivalent of running a marathon with a broken ankle. You can keep going. The question is whether you should.

The Bigger Picture

The oncolytic virus field sits at an awkward crossroads. The science is genuinely exciting: engineering viruses to selectively destroy cancer cells while training the immune system is one of oncology's most creative ideas. RP1's IGNYTE data showed real, durable responses in patients who had run out of options, with three-year survival rates of 54.8% and a safety profile that was remarkably clean (no treatment-related deaths).

But exciting science and approvable science are two different things. The FDA isn't questioning whether oncolytic viruses can work; it's demanding proof that they do work, in properly controlled studies that separate signal from noise. Until companies in this space design trials that meet that standard, we'll keep seeing promising data followed by rejection letters.

Replimune bet big on a single-arm trial being enough. The FDA called that bluff. Twice.

Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of

Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.